Aerogen,(www.aerogen.com) the innovative medical device and drug delivery company, has announced receipt of authorisation to market its Aeroneb Pro and Aeroneb Go products in China. The Aeroneb Pro is a patented vibrating mesh nebuliser which creates a fine particle aerosol for targeted drug delivery to the lungs. This unique, easy to use, multi-patient nebuliser is aimed predominately at the critical care market for treatment of a broad spectrum of patient respiratory conditions. Aerogen has also received approval for its home care device, the Aeroneb Go. Based on the same vibrating mesh technology, the Aeroneb Go brings hospital grade efficiency to inhaled drug treatment in the home.
“Aerogen is confident of a strong entry into the Chinese market. We expect to see Aerogen products in use in China by the end of March 2012, which will be a significant milestone in our planned move into emergent, high-growth regional markets.”
Aerogen, an Irish medical device company that currently sells its high-performance products in 65 countries, is continually expanding its operations into new markets. John Power, Aerogen CEO commented "The rapidly growing Chinese market is receptive to international products of the highest standard, and plays a key role in Aerogen's ambitious plans for growth. We are looking forward to being a part of that market, and bringing to Chinese patients for the first time the benefits enjoyed by users of our products across the globe."
Aerogen worked closely with Gaelmed, its distribution partner in China, to secure the approval from the State Food and Drug Administration (SFDA) for registration of two products from Aerogen. Gaelmed will act as a distribution channel for Aerogen, actively promoting and selling both the Aeroneb Pro and the Aeroneb Go within China.
Chinese annual spending on healthcare has an attractive 20% growth rate, representing a significant opportunity for advanced technologies to flourish. Aerogen is no stranger to high growth, having increased sales 30% year on year since its management buyout in 2008, an achievement recently recognised with the award of the Ruban d'Honneur for its international growth strategy at the European Business Awards.
"Aerogen is confident of a strong entry into the Chinese market. We expect to see Aerogen products in use in China by the end of March 2012, which will be a significant milestone in our planned move into emergent, high-growth regional markets." John Power said.
Ultrasound technology shows promise in detecting thoracic surface vibrations